Scholars@Duke

Moving beyond traditional clinical trial endpoints: patient-reported outcomes illuminate the patient experience of novel AML therapies.

Publication ,  Journal Article
LeBlanc, TW
Published in: Leuk Lymphoma
May 2023
Published version (DOI) Link to item

Duke Scholars

Thomas William LeBlanc
Author Thomas William LeBlanc Medicine, Hematologic Malignancies and Cellular Therapy

Published In

Leuk Lymphoma

DOI

10.1080/10428194.2023.2208696

EISSN

1029-2403

Publication Date

May 2023

Volume

64

Issue

5

Start / End Page

910 / 912

Location

United States

Related Subject Headings

  • Quality of Life
  • Patient Reported Outcome Measures
  • Leukemia, Myeloid, Acute
  • Immunology
  • Humans
  • 3201 Cardiovascular medicine and haematology
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
LeBlanc, T. W. (2023). Moving beyond traditional clinical trial endpoints: patient-reported outcomes illuminate the patient experience of novel AML therapies. Leuk Lymphoma, 64(5), 910–912. https://doi.org/10.1080/10428194.2023.2208696
LeBlanc, Thomas W. “Moving beyond traditional clinical trial endpoints: patient-reported outcomes illuminate the patient experience of novel AML therapies.” Leuk Lymphoma 64, no. 5 (May 2023): 910–12. https://doi.org/10.1080/10428194.2023.2208696.
LeBlanc, Thomas W. “Moving beyond traditional clinical trial endpoints: patient-reported outcomes illuminate the patient experience of novel AML therapies.” Leuk Lymphoma, vol. 64, no. 5, May 2023, pp. 910–12. Pubmed, doi:10.1080/10428194.2023.2208696.

Published In

Leuk Lymphoma

DOI

10.1080/10428194.2023.2208696

EISSN

1029-2403

Publication Date

May 2023

Volume

64

Issue

5

Start / End Page

910 / 912

Location

United States

Related Subject Headings

  • Quality of Life
  • Patient Reported Outcome Measures
  • Leukemia, Myeloid, Acute
  • Immunology
  • Humans
  • 3201 Cardiovascular medicine and haematology
  • 1103 Clinical Sciences